Improvement of quality of medications through implementing the six sigma methodology
The increased competition in the global pharmaceutical market and the necessity to reach higher levels of quality of the pharmaceutical products force the manufacturers to seek and adopt more effective and reliable quality management methods and techniques which allow them to introduce products with the highest possible quality level and reduced quality costs while maintaining conformance to the pharmaceutical GMPs, technical and legislative requirements. One of the popular modern quality management methodologies is Six Sigma, which proved its high ability to increase business profits and competitiveness within more than 30 years of implementation in manufacturing and service sectors. Recently, Six Sigma methodology has been adopted by global pharmaceutical companies such as Baxter, Eli Lilly, Johnson & Johnson and Novartis and obtained considerable benefits from its abilities. This research aims at investigating the possibility to improve the quality of medications through implementing the six sigma methodology, and to find out what benefits a pharmaceutical company can get through the implementation of this methodology. A case study was conducted in a pharmaceutical company in Syria (Orient-Pharma) in order to examine the effectiveness and advantages ofSix Sigma methodology. For this purpose, a quality improvement project was conducted using DMAIC roadmap to enhance the quality for one of the main products of the company. The obtained results of DMAIC project showed an enhanced process capability, an enhanced process Sigma level, decreased variability in the process outputs, as a result the quality of the medication had been enhanced sufficiently. As a conclusion, considerable benefits can be obtained through implementing Six Sigma methodology in the pharmaceutical industry to improve the medications quality and the production processes as well
Keywords: quality improvement, six sigma methodology, pharmaceutical industry, DMAIC methodology
References
1. D. V. Antipov, Yu. G. Gushyan, Yu. S. Klochkov, Yu. S. Eliseev, A. N. Chekmarev. Evaluation of the functioning of the system of logistics management of the quality of the technological process//Izvestiya Samarskogoauchnogo center of the Russian Academy of Sciences. 2016. Vol. 18. No. 4-1. P. 45-48.
2. K. B. Farris, D. M. Kirking (1993). Assessing the quality of pharmaceutical care II. Application of concepts of quality assessment from medical care//Annals of Pharmacotherapy, 27(2), 215-223.
3. I. H. T. Guideline (2005). Pharmaceutical development Q8.
4. I. H. T. Guideline (2008). Pharmaceutical quality system Q10.
5. I. H. T. Guideline (2005). Quality risk management Q9.
6. Y. S. Klochkov, A. D. Volgina, A. A. Karsuntseva, T. S. Selezneva, A. Yu. Gazizulina. Development of a product certification model based on QFD // Vector of the science of Togliatti State University. 2013. No. 4 (26). P. 111-113.
7. International Organization for Standardization (2015). Quality management systems — Fundamentals and vocabulary.
8. X. Y. Lawrence (2008). Pharmaceutical quality by design: product and process development, understanding, and control//Pharmaceutical research, 25 (4), 781-791.
9. T. Lofthouse (1999). The Taguchi loss function//Work Study, 48(6), 218-223.
10. M. M. A. Potdar (2006). Pharmaceutical quality assurance. Pragati Books Pvt. Ltd.
11. A. Rostami-Hodjegan, P. R. Jackson, G. T. Tucker (1994). Sensitivity of indirect metrics for assessing «rate» in bioequivalence studies — moving the «goalposts» or changing the «game»//Journal of pharmaceutical sciences, 83(11), 1554-1557.
12. R. K. Roy (2010). A primer on the Taguchi method. Society of Manufacturing Engineers.
13. G. Taguchi (1986). Introduction to quality engineering: designing quality into products and processes (No. 658.562 T3).
14. G. Taguchi (1993). Methods for Evaluating Quality. ASME press.
15. G. Taguchi, S. Chowdhury, Y. Wu (2005). Taguchi's quality engineering handbook (Vol. 1736). Hoboken, NJ: John Wiley & Sons.
16. J. F. van Leeuwen, M. J. Nauta, D. De Kaste, Y. M. C. F. Odekerken-Rombouts, M. T. Oldenhof, M. J. Vredenbregt, D. M. Barends (2009). Risk analysis by FMEA as an element of analytical validation//Journal of pharmaceutical and biomedical analysis, 50(5), 1085-1087.
17. L. X. Yu, A. Raw, R. Lionberger, R. Rajagopalan, L. M. Lee, F. Holcombe, R. Adams (2007). US FDA question-based review for generic drugs: A new pharmaceutical quality assessment system//Journal of Generic Medicines, 4 (4), 239-246.
